Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 -0.0100217864923749 -0.0261437908496733
Stock impact report

Complete and Durable Responses Observed in OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer

UroGen Pharma Ltd (URGN)  More Company Research Source: Business Wire
Last urogen pharma ltd earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF 65% Complete Response Rate at Three MonthsDuration of Response Estimated to be 72.5% at Nine Months (12-Months from Initiation of Therapy) by Kaplan-Meier Method; Median Duration of Response was Not ReachedTreatment with UGN-102 was Generally Well Tolerated, with Mostly Mild to Moderate Adverse Events Reported Phase 3 Pivotal Trial Evaluating UGN-102 Versus Current Standard of Care Expected to Start by Year-End PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) today announced final topline results from the single-arm, open-label OPTIMA II Phase 2b trial evaluating the efficacy and safety of investigational UGN-102 (mitomycin) for intravesical solution in patients with low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC). As previously reported, 65% (41/63) of patients receiving UGN-102 achieved a complete response (CR) three months after the start of therapy. In this subset of patients, duration of response at nine months (12-months from st [Read more]
Impact snapshot Event time: URGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
URGN alerts

from News Quantified
Opt-in for
URGN alerts

from News Quantified